Biological
BNT162b2 Vaccine
BNT162b2 Vaccine is a biological therapy with 6 clinical trials. Currently 1 active trials ongoing. Historical success rate of 33.3%.
Total Trials
6
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
1(17%)
Results Posted
200%(2 trials)
Terminated
2(33%)
Phase Distribution
Ph phase_4
1
17%
Ph phase_3
3
50%
Ph phase_2
1
17%
Phase Distribution
0
Early Stage
1
Mid Stage
4
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
3(60.0%)
Phase 4Post-market surveillance
1(20.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
1
trials recruiting
Total Trials
6
all time
Status Distribution
Active(1)
Completed(1)
Terminated(2)
Other(2)
Detailed Status
unknown2
Terminated2
Active, not recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
1
Success Rate
33.3%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (20.0%)
Phase 33 (60.0%)
Phase 41 (20.0%)
Trials by Status
unknown233%
active_not_recruiting117%
completed117%
terminated233%
Recent Activity
1 active trials
Showing 5 of 6
active_not_recruitingphase_3
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
NCT07300839
terminatedphase_2
Booster Dose Trial
NCT05016622
terminatedphase_3
COVID-19 3rd Dose Vaccine in Transplant Patients
NCT05047640
completed
Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong
NCT04898946
unknownphase_4
Fourth BNT162b2 COVID-19 Vaccine Dose
NCT05231005
Clinical Trials (6)
Showing 6 of 6 trials
NCT07300839Phase 3
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
NCT05016622Phase 2
Booster Dose Trial
NCT05047640Phase 3
COVID-19 3rd Dose Vaccine in Transplant Patients
NCT04898946
Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong
NCT05231005Phase 4
Fourth BNT162b2 COVID-19 Vaccine Dose
NCT05293665Phase 3
Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine
All 6 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 6